Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), A. Szenik(Centre Hospitalier Universitaire de Besançon), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), Thierry Lesimple, L. Machet(Université de Tours), Florent Grange(Centre Hospitalier Universitaire de Reims), Jean‐Jacques Grob, A. Denden(Novartis (France)), Laurent Mortier, Christophe Bédane, Caroline Robert(Centre National de la Recherche Scientifique), H. Maillard(Université de Tours), Charlée Nardin(CHU Dijon Bourgogne), Eve‐Marie Neidhardt(Centre Léon Bérard), O. Dereure(Beth Israel Deaconess Medical Center)
Cited by 13
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k